In the US, Lucentis (ranibizumab ophthalmic) is a member of the drug class anti-angiogenic ophthalmic agents and is used to treat Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration and Macular Edema.
Ingredient matches for Lucentis
Levothyroxine sodium (a derivative of Levothyroxine) is reported as an ingredient of Lucentis in the following countries:
Ranibizumab is reported as an ingredient of Lucentis in the following countries:
- Croatia (Hrvatska)
- Czech Republic
- Hong Kong
- New Zealand
- Russian Federation
- South Africa
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.